305 related articles for article (PubMed ID: 30834654)
1. Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis.
MacDonald SC; McElrath TF; Hernández-Díaz S
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):556-560. PubMed ID: 30834654
[TBL] [Abstract][Full Text] [Related]
2. Glatiramer acetate during early pregnancy: A prospective cohort study.
Herbstritt S; Langer-Gould A; Rockhoff M; Haghikia A; Queisser-Wahrendorf A; Gold R; Hellwig K
Mult Scler; 2016 May; 22(6):810-6. PubMed ID: 26754804
[TBL] [Abstract][Full Text] [Related]
3. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry.
Thiel S; Langer-Gould A; Rockhoff M; Haghikia A; Queisser-Wahrendorf A; Gold R; Hellwig K
Mult Scler; 2016 May; 22(6):801-9. PubMed ID: 26920382
[TBL] [Abstract][Full Text] [Related]
4. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
Wijnands JMA; Zhu F; Kingwell E; Fisk JD; Evans C; Marrie RA; Zhao Y; Tremlett H
J Neurol Neurosurg Psychiatry; 2018 Oct; 89(10):1050-1056. PubMed ID: 29602795
[TBL] [Abstract][Full Text] [Related]
5. Trends in the use of disease-modifying therapies among reproductive-aged women with multiple sclerosis in the United States from 2010 to 2019.
Duchesneau ED; Kinlaw AC; Jonsson Funk M; Pate V; Lund JL
Pharmacoepidemiol Drug Saf; 2022 Apr; 31(4):481-487. PubMed ID: 35088492
[TBL] [Abstract][Full Text] [Related]
6. [Disease modifying drugs in multiple sclerosis and pregnancy].
Tur C; Tintoré M; Aguilera C
Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277
[No Abstract] [Full Text] [Related]
7. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
[TBL] [Abstract][Full Text] [Related]
8. Pregnancy and fetal outcomes following paternal exposure to glatiramer acetate.
Kaplan S; Dragut CF; Ghimpeteanu A
Curr Med Res Opin; 2024 May; 40(5):821-825. PubMed ID: 38577712
[TBL] [Abstract][Full Text] [Related]
9. Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy.
Berenguer-Ruiz L; Gimenez-Martinez J; Palazón-Bru A; Sempere AP
J Neurol; 2019 Oct; 266(10):2512-2517. PubMed ID: 31256279
[TBL] [Abstract][Full Text] [Related]
10. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.
Lu E; Wang BW; Guimond C; Synnes A; Sadovnick D; Tremlett H
Neurology; 2012 Sep; 79(11):1130-5. PubMed ID: 22933738
[TBL] [Abstract][Full Text] [Related]
11. Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study.
Pecori C; Giannini M; Portaccio E; Ghezzi A; Hakiki B; Pastò L; Razzolini L; Sturchio A; De Giglio L; Pozzilli C; Paolicelli D; Trojano M; Marrosu MG; Patti F; Mancardi GL; Solaro C; Totaro R; Tola MR; De Luca G; Lugaresi A; Moiola L; Martinelli V; Comi G; Amato MP;
BMC Neurol; 2014 May; 14():114. PubMed ID: 24884599
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Bonafede MM; Johnson BH; Wenten M; Watson C
Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
[TBL] [Abstract][Full Text] [Related]
13. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis.
Sandberg-Wollheim M; Frank D; Goodwin TM; Giesser B; Lopez-Bresnahan M; Stam-Moraga M; Chang P; Francis GS
Neurology; 2005 Sep; 65(6):802-6. PubMed ID: 16093457
[TBL] [Abstract][Full Text] [Related]
14. Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry.
Hellwig K; Geissbuehler Y; Sabidó M; Popescu C; Adamo A; Klinger J; Ornoy A; Huppke P;
J Neurol; 2020 Jun; 267(6):1715-1723. PubMed ID: 32100126
[TBL] [Abstract][Full Text] [Related]
15. Pregnancy and Family Planning in Multiple Sclerosis.
Langer-Gould AM
Continuum (Minneap Minn); 2019 Jun; 25(3):773-792. PubMed ID: 31162316
[TBL] [Abstract][Full Text] [Related]
16. Use of multiple sclerosis disease-modifying therapies during pregnancy in France: Nationwide study between 2010 and 2021.
Swital M; Drouin J; Miranda S; Bakchine S; Botton J; Dray-Spira R
Mult Scler; 2024 Feb; 30(2):227-237. PubMed ID: 38281078
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy in women with multiple sclerosis in France from 2010 to 2015: Incidence, outcomes, and exposure to disease-modifying therapies.
Tillaut H; Degrémont A; Kerbrat S; Roux J; Le Page E; Mainguy C; Duros S; Polard E; Leray E
Mult Scler; 2022 Apr; 28(5):778-789. PubMed ID: 34410176
[TBL] [Abstract][Full Text] [Related]
18. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
Portaccio E; Annovazzi P; Ghezzi A; Zaffaroni M; Moiola L; Martinelli V; Lanzillo R; Brescia Morra V; Rinaldi F; Gallo P; Tortorella C; Paolicelli D; Pozzilli C; De Giglio L; Cavalla P; Cocco E; Marrosu MG; Patti F; Solaro C; Bellantonio P; Uccelli A; Laroni A; Pastò L; Giannini M; Trojano M; Comi G; Amato MP;
Neurology; 2018 Mar; 90(10):e823-e831. PubMed ID: 29438046
[TBL] [Abstract][Full Text] [Related]
19. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
Chen J; Taylor BV; Blizzard L; Simpson S; Palmer AJ; van der Mei IAF
J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1200-1207. PubMed ID: 29921609
[TBL] [Abstract][Full Text] [Related]
20. Treatment of multiple sclerosis during pregnancy - safety considerations.
Thöne J; Thiel S; Gold R; Hellwig K
Expert Opin Drug Saf; 2017 May; 16(5):523-534. PubMed ID: 28333552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
